Eli Lilly and Company

What does Eli Lilly make?
Eli Lilly makes prescription pharmaceuticals across several therapeutic areas. Its most important products are Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity), which are dual GIP/GLP-1 receptor agonists. The company also makes Verzenio (breast cancer), Trulicity (diabetes), Taltz (psoriasis), Humalog (insulin), and Emgality (migraine).

Is Eli Lilly publicly traded?
Yes, Eli Lilly and Company is listed on NYSE under ticker LLY. Major institutional shareholders include Vanguard Group, BlackRock, and State Street.

Who founded Eli Lilly?
Eli Lilly was founded in 1876 in Indianapolis, Indiana by Colonel Eli Lilly, a Civil War veteran and pharmacist. The company made its first major breakthrough in 1923 when it produced commercial quantities of insulin.

Where is Eli Lilly headquartered?
Eli Lilly is headquartered in Indianapolis, Indiana, USA, where the company was founded in 1876. The company operates research and development centers, manufacturing facilities, and commercial operations in more than 120 countries.

What is Mounjaro and Zepbound?
Mounjaro and Zepbound both contain tirzepatide, a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. Mounjaro is approved for type 2 diabetes, while Zepbound is approved for obesity. Tirzepatide has demonstrated superior efficacy to existing GLP-1 drugs in clinical trials, with patients losing an average of approximately 20% of their body weight in obesity trials.

Who owns Eli Lilly?
Eli Lilly and Company is publicly traded on NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. David Ricks serves as Chairman and CEO.

Eli Lilly and Company was founded in 1876 in Indianapolis, Indiana by Colonel Eli Lilly, a Civil War veteran and pharmacist. Lilly was dissatisfied with the poor quality of medicines available at the time and established his company to produce pharmaceutical products of consistent quality and purity.

Eli Lilly made its first major scientific breakthrough in 1923, when the company partnered with University of Toronto researchers to produce commercial quantities of insulin for the treatment of diabetes. This saved countless lives and established Eli Lilly as a leader in diabetes care, a position it has maintained for more than a century.

The company developed numerous important pharmaceutical products through the 20th century, including Darvon (a pain reliever), Seconal (a sedative), and Keflex (an antibiotic). Eli Lilly also produced the first commercial quantities of penicillin during World War II.

Eli Lilly launched Prozac (fluoxetine) in 1988, which became one of the best-selling antidepressants in history. Prozac generated billions of dollars in revenue for Eli Lilly through the 1990s and early 2000s.

The company launched Zyprexa (olanzapine) for schizophrenia in 1996 and Cymbalta (duloxetine) for depression in 2004, both major commercial products. Eli Lilly entered the GLP-1 receptor agonist market with Trulicity (dulaglutide) for type 2 diabetes in 2014.

The company received FDA approval for Mounjaro (tirzepatide) for type 2 diabetes in May 2022 and for Zepbound (tirzepatide) for obesity in November 2023. Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrated superior efficacy to existing GLP-1 drugs in clinical trials, with patients losing an average of approximately 20% of their body weight in obesity trials. The commercial launch of Mounjaro and Zepbound drove explosive revenue growth, with Eli Lilly's annual revenue growing from approximately $28 billion in 2022 to approximately $45 billion in 2024.

Eli Lilly has implemented comprehensive sustainability and ethical practices focused on environmental responsibility, pharmaceutical innovation, and global health access. The company maintains ESG reporting frameworks and has set ambitious sustainability goals including renewable energy purchasing and environmental innovation initiatives.

Environmental sustainability initiatives include purchasing 58% of electricity from renewable sources in 2024, doubling renewable energy purchasing compared to 2023. The company has established goals for 100% plastic waste repurposing by 2030, with at least 90% recycled or reused, and zero waste to landfill initiatives.

Manufacturing sustainability focuses on green chemistry principles, environmental innovation in product development, and sustainable manufacturing processes across global facilities. Eli Lilly works to embed environmental considerations early in the product development lifecycle through green chemistry and end-product engineering.

The company maintains strong ethical standards regarding pharmaceutical pricing, patient access, and clinical research integrity. Eli Lilly has implemented insulin pricing caps and patient assistance programs to improve medication accessibility while maintaining ethical business practices in the pharmaceutical industry.

Eli Lilly has received extensive recognition for pharmaceutical innovation, medical breakthroughs, and corporate achievement in the global healthcare industry.

• Pharmaceutical Excellence Awards: Multiple awards for drug development innovation and therapeutic breakthroughs
• Medical Innovation Recognition: Awards for tirzepatide development and GLP-1/GIP receptor agonist innovation
• Research & Development Excellence: Recognition for pharmaceutical R&D investment and pipeline development
• Oncology Leadership Awards: Recognition for cancer treatment innovation and breast cancer therapies
• Diabetes Care Recognition: Awards for diabetes treatment innovation and insulin therapy advancement
• Workplace Excellence: Various awards for workplace culture, diversity, and pharmaceutical industry leadership
• Corporate Responsibility Awards: Recognition for insulin pricing initiatives and patient access programs
• Scientific Achievement Awards: Recognition for pharmaceutical research and medical breakthrough discoveries
• Global Leadership Recognition: Awards for international pharmaceutical market leadership and innovation
• Sustainability Awards: Recognition for environmental initiatives and sustainable pharmaceutical practices

The company has been consistently recognized for its role in advancing medical treatment options and developing innovative pharmaceutical therapies that improve patient outcomes globally.

Eli Lilly has faced significant scrutiny regarding the pricing of its insulin products. In 2023, the company announced it would cap the out-of-pocket cost of its insulin products at $35 per month for US patients, following years of criticism about insulin pricing.

The company has also faced scrutiny regarding the pricing of Mounjaro and Zepbound, which cost approximately $1,000 per month before insurance, limiting access for patients without adequate coverage.

Eli Lilly settled a lawsuit in 2009 for approximately $1.4 billion related to the off-label marketing of Zyprexa (olanzapine) for uses not approved by the FDA.